Tumor size is a major determinant of recurrence in patients with resectable gastrointestinal stromal tumor
- 31 August 2007
- journal article
- Published by Elsevier in The American Journal of Surgery
- Vol. 194 (2) , 148-152
- https://doi.org/10.1016/j.amjsurg.2006.10.033
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Factors Associated With Disease Progression in Patients With Gastrointestinal Stromal Tumors in the Pre-Imatinib EraAmerican Journal of Clinical Pathology, 2005
- Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumorsThe Esophagus, 2005
- Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate eraCancer, 2005
- Clinical presentation of gastrointestinal stromal tumors and treatment of operable diseaseEuropean Journal Of Cancer, 2002
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Diagnosis of gastrointestinal stromal tumors: A consensus approachHuman Pathology, 2002
- Clinical management of gastrointestinal stromal tumors: Before and after STI-571Human Pathology, 2002
- Imatinib Mesylate — A New Oral Targeted TherapyNew England Journal of Medicine, 2002
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998
- Gastric stromal tumors Reappraisal of histogenesisThe American Journal of Surgical Pathology, 1983